CORCEPT THERAPEUTICS INC (1CORT.MI) Stock Fundamental Analysis

BIT:1CORT • US2183521028

38.02 EUR
-24.68 (-39.36%)
Last: Jan 26, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

1CORT gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 52 industry peers in the Pharmaceuticals industry. While 1CORT has a great health rating, its profitability is only average at the moment. 1CORT is valued quite expensively, but it does show have an excellent growth rating. With these ratings, 1CORT could be worth investigating further for growth investing!.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • 1CORT had positive earnings in the past year.
  • 1CORT had a positive operating cash flow in the past year.
  • 1CORT had positive earnings in each of the past 5 years.
  • Each year in the past 5 years 1CORT had a positive operating cash flow.
1CORT.MI Yearly Net Income VS EBIT VS OCF VS FCF1CORT.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

  • The Return On Assets of 1CORT (12.88%) is better than 80.00% of its industry peers.
  • Looking at the Return On Equity, with a value of 16.79%, 1CORT is in line with its industry, outperforming 56.36% of the companies in the same industry.
  • 1CORT has a Return On Invested Capital (8.69%) which is comparable to the rest of the industry.
  • The Average Return On Invested Capital over the past 3 years for 1CORT is above the industry average of 14.45%.
  • The last Return On Invested Capital (8.69%) for 1CORT is well below the 3 year average (17.94%), which needs to be investigated, but indicates that 1CORT had better years and this may not be a problem.
Industry RankSector Rank
ROA 12.88%
ROE 16.79%
ROIC 8.69%
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
1CORT.MI Yearly ROA, ROE, ROIC1CORT.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

1.3 Margins

  • The Profit Margin of 1CORT (14.32%) is comparable to the rest of the industry.
  • 1CORT's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 8.85%, 1CORT is doing worse than 63.64% of the companies in the same industry.
  • 1CORT's Operating Margin has declined in the last couple of years.
  • With an excellent Gross Margin value of 98.19%, 1CORT belongs to the best of the industry, outperforming 98.18% of the companies in the same industry.
  • 1CORT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.85%
PM (TTM) 14.32%
GM 98.19%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
1CORT.MI Yearly Profit, Operating, Gross Margins1CORT.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • 1CORT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for 1CORT has been increased compared to 1 year ago.
  • Compared to 5 years ago, 1CORT has less shares outstanding
  • 1CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
1CORT.MI Yearly Shares Outstanding1CORT.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
1CORT.MI Yearly Total Debt VS Total Assets1CORT.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • 1CORT has an Altman-Z score of 17.52. This indicates that 1CORT is financially healthy and has little risk of bankruptcy at the moment.
  • 1CORT's Altman-Z score of 17.52 is amongst the best of the industry. 1CORT outperforms 96.36% of its industry peers.
  • There is no outstanding debt for 1CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 17.52
ROIC/WACC0.92
WACC9.42%
1CORT.MI Yearly LT Debt VS Equity VS FCF1CORT.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

  • 1CORT has a Current Ratio of 3.14. This indicates that 1CORT is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of 1CORT (3.14) is better than 89.09% of its industry peers.
  • A Quick Ratio of 3.07 indicates that 1CORT has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.07, 1CORT belongs to the top of the industry, outperforming 92.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 3.07
1CORT.MI Yearly Current Assets VS Current Liabilites1CORT.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The earnings per share for 1CORT have decreased strongly by -30.16% in the last year.
  • Measured over the past years, 1CORT shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.71% on average per year.
  • 1CORT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.92%.
  • Measured over the past years, 1CORT shows a quite strong growth in Revenue. The Revenue has been growing by 17.11% on average per year.
EPS 1Y (TTM)-30.16%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-60.98%
Revenue 1Y (TTM)17.92%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%13.75%

3.2 Future

  • 1CORT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.06% yearly.
  • Based on estimates for the next years, 1CORT will show a very strong growth in Revenue. The Revenue will grow by 23.55% on average per year.
EPS Next Y-23.36%
EPS Next 2Y-29.36%
EPS Next 3Y36.25%
EPS Next 5Y44.06%
Revenue Next Year17.6%
Revenue Next 2Y23.46%
Revenue Next 3Y25.84%
Revenue Next 5Y23.55%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
1CORT.MI Yearly Revenue VS Estimates1CORT.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
1CORT.MI Yearly EPS VS Estimates1CORT.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 50.69 indicates a quite expensive valuation of 1CORT.
  • Based on the Price/Earnings ratio, 1CORT is valued a bit more expensive than the industry average as 69.09% of the companies are valued more cheaply.
  • Compared to an average S&P500 Price/Earnings ratio of 27.16, 1CORT is valued quite expensively.
  • Based on the Price/Forward Earnings ratio of 72.46, the valuation of 1CORT can be described as expensive.
  • 1CORT's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. 1CORT is more expensive than 74.55% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.10, 1CORT is valued quite expensively.
Industry RankSector Rank
PE 50.69
Fwd PE 72.46
1CORT.MI Price Earnings VS Forward Price Earnings1CORT.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 72.73% of the companies in the same industry are cheaper than 1CORT, based on the Enterprise Value to EBITDA ratio.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as 1CORT.
Industry RankSector Rank
P/FCF 29.01
EV/EBITDA 60.19
1CORT.MI Per share data1CORT.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

  • The decent profitability rating of 1CORT may justify a higher PE ratio.
  • A more expensive valuation may be justified as 1CORT's earnings are expected to grow with 36.25% in the coming years.
PEG (NY)N/A
PEG (5Y)5.22
EPS Next 2Y-29.36%
EPS Next 3Y36.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for 1CORT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CORCEPT THERAPEUTICS INC

BIT:1CORT (1/26/2026, 7:00:00 PM)

38.02

-24.68 (-39.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04
Earnings (Next)02-18
Inst Owners75.42%
Inst Owner ChangeN/A
Ins Owners6.65%
Ins Owner ChangeN/A
Market Cap4.00B
Revenue(TTM)741.17M
Net Income(TTM)106.11M
Analysts75
Price Target82.87 (117.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.91%
Min EPS beat(2)16.19%
Max EPS beat(2)51.63%
EPS beat(4)3
Avg EPS beat(4)11.15%
Min EPS beat(4)-40.2%
Max EPS beat(4)51.63%
EPS beat(8)7
Avg EPS beat(8)17.67%
EPS beat(12)9
Avg EPS beat(12)13.54%
EPS beat(16)12
Avg EPS beat(16)12.14%
Revenue beat(2)0
Avg Revenue beat(2)-5.62%
Min Revenue beat(2)-6.85%
Max Revenue beat(2)-4.4%
Revenue beat(4)0
Avg Revenue beat(4)-8.72%
Min Revenue beat(4)-13.38%
Max Revenue beat(4)-4.4%
Revenue beat(8)4
Avg Revenue beat(8)-2.84%
Revenue beat(12)6
Avg Revenue beat(12)-1.77%
Revenue beat(16)7
Avg Revenue beat(16)-2.44%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)-50.34%
EPS NQ rev (3m)-50.34%
EPS NY rev (1m)-32.37%
EPS NY rev (3m)-32.37%
Revenue NQ rev (1m)-13.41%
Revenue NQ rev (3m)-13.41%
Revenue NY rev (1m)-9.38%
Revenue NY rev (3m)-9.38%
Valuation
Industry RankSector Rank
PE 50.69
Fwd PE 72.46
P/S 6.36
P/FCF 29.01
P/OCF 28.96
P/B 7.46
P/tB 7.46
EV/EBITDA 60.19
EPS(TTM)0.75
EY1.97%
EPS(NY)0.52
Fwd EY1.38%
FCF(TTM)1.31
FCFY3.45%
OCF(TTM)1.31
OCFY3.45%
SpS5.97
BVpS5.09
TBVpS5.09
PEG (NY)N/A
PEG (5Y)5.22
Graham Number9.27
Profitability
Industry RankSector Rank
ROA 12.88%
ROE 16.79%
ROCE 10.07%
ROIC 8.69%
ROICexc 24.92%
ROICexgc 24.92%
OM 8.85%
PM (TTM) 14.32%
GM 98.19%
FCFM 21.93%
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexgc growth 3Y-18.86%
ROICexgc growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 36.2%
Cap/Sales 0.04%
Interest Coverage 250
Cash Conversion 245.43%
Profit Quality 153.21%
Current Ratio 3.14
Quick Ratio 3.07
Altman-Z 17.52
F-Score6
WACC9.42%
ROIC/WACC0.92
Cap/Depr(3y)112.18%
Cap/Depr(5y)124.4%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)-30.16%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-60.98%
EPS Next Y-23.36%
EPS Next 2Y-29.36%
EPS Next 3Y36.25%
EPS Next 5Y44.06%
Revenue 1Y (TTM)17.92%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%13.75%
Revenue Next Year17.6%
Revenue Next 2Y23.46%
Revenue Next 3Y25.84%
Revenue Next 5Y23.55%
EBIT growth 1Y-54.26%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year-24.4%
EBIT Next 3Y37.86%
EBIT Next 5YN/A
FCF growth 1Y5.22%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y5.34%
OCF growth 3Y5.66%
OCF growth 5Y7.79%

CORCEPT THERAPEUTICS INC / 1CORT.MI FAQ

What is the fundamental rating for 1CORT stock?

ChartMill assigns a fundamental rating of 7 / 10 to 1CORT.MI.


Can you provide the valuation status for CORCEPT THERAPEUTICS INC?

ChartMill assigns a valuation rating of 3 / 10 to CORCEPT THERAPEUTICS INC (1CORT.MI). This can be considered as Overvalued.


What is the profitability of 1CORT stock?

CORCEPT THERAPEUTICS INC (1CORT.MI) has a profitability rating of 7 / 10.


Can you provide the financial health for 1CORT stock?

The financial health rating of CORCEPT THERAPEUTICS INC (1CORT.MI) is 9 / 10.


Can you provide the expected EPS growth for 1CORT stock?

The Earnings per Share (EPS) of CORCEPT THERAPEUTICS INC (1CORT.MI) is expected to decline by -23.36% in the next year.